Holdings
Jones Hill Capital LP
As of Jun 30, 2026, Jones Hill Capital LP reported 26 positions worth US$428M. Largest: Biomarin Pharmaceutical Inc., Gilead Sciences, Inc. and Arcutis Biotherapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Biomarin Pharmaceutical Inc. | 1.43M | US$81.9M | +163K | Jun 30, 2026 |
| Gilead Sciences, Inc. | 343K | US$43.3M | new | Jun 30, 2026 |
| Arcutis Biotherapeutics, Inc. | 1.09M | US$28.6M | new | Jun 30, 2026 |
| Madrigal Pharmaceuticals, Inc. | 52,545 | US$28.2M | new | Jun 30, 2026 |
| Bicara Therapeutics Inc. | 893K | US$26.5M | −368K | Jun 30, 2026 |
| Relmada Therapeutics, Inc. | 3.66M | US$25.3M | +3.31M | Jun 30, 2026 |
| Trevi Therapeutics, Inc. | 1.34M | US$25M | +969K | Jun 30, 2026 |
| Xenon Pharmaceuticals Inc. | 368K | US$22.2M | new | Jun 30, 2026 |
| Ani Pharmaceuticals, Inc. | 234K | US$19.4M | −84,783 | Jun 30, 2026 |
| Amylyx Pharmaceuticals, Inc. | 894K | US$16.1M | −705K | Jun 30, 2026 |